Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Compensatory erythropoiesis has no impact on the outcome of the in vivo Pig-a mutation assay in rats following treatment with the haemolytic agent 2-butoxyethanol.

Kenyon MO, Coffing SL, Ackerman JI, Gunther WC, Dertinger SD, Criswell K, Dobo KL.

Mutagenesis. 2015 May;30(3):325-34. doi: 10.1093/mutage/geu051. Epub 2015 Mar 27.

PMID:
25820171
2.

Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28-day studies.

Coffing SL, Kenyon MO, Ackerman JI, Shutsky TJ, Dobo KL.

Environ Mol Mutagen. 2015 Apr;56(3):322-32. doi: 10.1002/em.21910. Epub 2014 Sep 17.

PMID:
25229874
3.

Evaluation of the Pig-a, micronucleus, and comet assay endpoints in a 28-day study with ethyl methanesulfonate.

Gunther WC, Coffing SL, Dickinson DA, Engel ME, Fiedler RD, O'Lone SD, Sanok KE, Thiffeault CJ, Shutsky TJ, Schuler MJ, Dobo KL.

Environ Mol Mutagen. 2014 Jul;55(6):492-9. doi: 10.1002/em.21863. Epub 2014 Mar 6.

PMID:
24599777
4.

Development and validation of an in vitro micronucleus assay platform in TK6 cells.

Sobol Z, Homiski ML, Dickinson DA, Spellman RA, Li D, Scott A, Cheung JR, Coffing SL, Munzner JB, Sanok KE, Gunther WC, Dobo KL, Schuler M.

Mutat Res. 2012 Jul 4;746(1):29-34. doi: 10.1016/j.mrgentox.2012.02.005. Epub 2012 Mar 13.

PMID:
22445949
5.

Report on stage III Pig-a mutation assays using N-ethyl-N-nitrosourea-comparison with other in vivo genotoxicity endpoints.

Cammerer Z, Bhalli JA, Cao X, Coffing SL, Dickinson D, Dobo KL, Dobrovolsky VN, Engel M, Fiedler RD, Gunther WC, Heflich RH, Pearce MG, Shaddock JG, Shutsky T, Thiffeault CJ, Schuler M.

Environ Mol Mutagen. 2011 Dec;52(9):721-30.

PMID:
22167886
6.

Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats.

Dobo KL, Fiedler RD, Gunther WC, Thiffeault CJ, Cammerer Z, Coffing SL, Shutsky T, Schuler M.

Mutat Res. 2011 Oct 9;725(1-2):13-21. doi: 10.1016/j.mrgentox.2011.06.005. Epub 2011 Jun 24.

7.

Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.

Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV Jr, Soliman VF, Schildknegt K.

Drug Metab Dispos. 2007 Jun;35(6):848-58. Epub 2007 Mar 7.

PMID:
17344339
8.

Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.

VanBrocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, Gilmore JL, Bryant I, Riese DJ 2nd.

J Med Chem. 2005 Nov 17;48(23):7445-56.

PMID:
16279804
9.

Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.

Hobbs SS, Cameron EM, Hammer RP, Le AT, Gallo RM, Blommel EN, Coffing SL, Chang H, Riese DJ 2nd.

Oncogene. 2004 Jan 29;23(4):883-93.

PMID:
14661053
10.

Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation.

Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, Andrew M, Blommel EN, Hammer RP, Chang H, Riese DJ 2nd.

Oncogene. 2002 Dec 5;21(55):8442-52.

11.

Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization.

Mu F, Coffing SL, Riese DJ 2nd, Geahlen RL, Verdier-Pinard P, Hamel TE, Johnson J, Cushman M.

J Med Chem. 2001 Feb 1;44(3):441-52.

PMID:
11462983
12.

Metabolic activation of 4H-cyclopenta[def]chrysene in human mammary carcinoma MCF-7 cell cultures.

Agarwal R, Coffing SL, Baird WM, Harvey RG, Dipple A.

Chem Res Toxicol. 1999 May;12(5):437-41.

PMID:
10328754
13.

Stable expression of human cytochrome P450 1B1 in V79 Chinese hamster cells and metabolically catalyzed DNA adduct formation of dibenzo[a,l]pyrene.

Luch A, Coffing SL, Tang YM, Schneider A, Soballa V, Greim H, Jefcoate CR, Seidel A, Greenlee WF, Baird WM, Doehmer J.

Chem Res Toxicol. 1998 Jun;11(6):686-95.

PMID:
9625737
15.

Metabolic activation of benzo[g]chrysene in the human mammary carcinoma cell line MCF-7.

Agarwal R, Coffing SL, Baird WM, Kiselyov AS, Harvey RG, Dipple A.

Cancer Res. 1997 Feb 1;57(3):415-9.

17.

Inhibition of benzo[a]pyrene metabolism by insulin, FITC-insulin and an FITC-insulin-antibody conjugate in the human hepatoma cell line HepG2.

Polzer RJ, Coffing SL, Marcus CB, Park SS, Gelboin HV, Baird WM.

Chem Biol Interact. 1995 Aug 18;97(3):307-18.

PMID:
7671346
18.
20.
21.

Effects of biochanin A on metabolism, DNA binding and mutagenicity of benzo[a]pyrene in mammalian cell cultures.

Chae YH, Coffing SL, Cook VM, Ho DK, Cassady JM, Baird WM.

Carcinogenesis. 1991 Nov;12(11):2001-6.

PMID:
1934284

Supplemental Content

Loading ...
Support Center